本研究的目的是评估全身[68 Ga]Ga-PSMA-11 PET/CT是否能提高与常规[68 Ga]Ga-PSMA-11 PET/CT相比，在生化复发前列腺癌患者中的检出率。纳入具有相似临床病理特征的200名生化复发前列腺癌患者，其中100名患者接受了早期全身[68 Ga]Ga-PSMA-11 PET/CT和利尿延迟全身[68 Ga]Ga-PSMA-11 PET/CT检查，另外100名患者接受了早期常规[68 Ga]Ga-PSMA-11 PET/CT和利尿延迟常规[68 Ga]Ga-PSMA-11 PET/CT检查。使用卡方检验和分层分析比较全身[68 Ga]Ga-PSMA-11 PET/CT和常规[68 Ga]Ga-PSMA-11 PET/CT的检出率。基于主观评分和客观参数比较全身[68 Ga]Ga-PSMA PET/CT和常规[68 Ga]Ga-PSMA-11 PET/CT的图像质量。主观评分从背景噪声和病变突出性方面使用5分制进行评分。客观参数通过SUVmax、SUVmean、SUV标准差（SD）和肝脏和臀大肌的信噪比（SNR）进行评估。还测量了复发病灶的SUVmax。全身[68 Ga]Ga-PSMA-11 PET/CT的肝脏SD显著低于常规[68 Ga]Ga-PSMA-11 PET/CT，SNR显著高于常规[68 Ga]Ga-PSMA-11 PET/CT，主观评价显著优于常规[68 Ga]Ga-PSMA-11 PET/CT。全身[68 Ga]Ga-PSMA PET/CT对前列腺癌生化复发的检出率显著高于常规[68 Ga]Ga-PSMA-11 PET/CT（91.0% vs. 74.0%，P=0.003）。全身[68 Ga]Ga-PSMA-11 PET/CT对Gleason得分≤8或PSA≤2 ng/ml的患者具有更好的检出效率。利尿延迟全身[68 Ga]Ga-PSMA-11 PET/CT的优势更为明显。全身[68 Ga]Ga-PSMA-11 PET/CT与常规[68 Ga]Ga-PSMA-11 PET/CT相比，在生化复发前列腺癌患者中能显著提高检出率。© 2023 Springer Nature公司授权Springer-Verlag GmbH Germany独家发表。

The purpose of this study was to assess whether total-body [68 Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared with conventional [68 Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer.Two hundred biochemical recurrent prostate cancer patients with similar clinicopathological characteristics were included, of whom 100 patients underwent early total-body [68 Ga]Ga-PSMA-11 PET/CT and diuretic-delayed total-body [68 Ga]Ga-PSMA-11 PET/CT, and the other 100 patients received early conventional [68 Ga]Ga-PSMA-11 PET/CT and diuretic-delayed conventional [68 Ga]Ga-PSMA-11 PET/CT. The detection rates of total-body [68 Ga]Ga-PSMA-11 PET/CT and conventional [68 Ga]Ga-PSMA-11 PET/CT were compared using a chi-square test and stratified analysis. The image quality of total-body [68 Ga]Ga-PSMA PET/CT and conventional [68 Ga]Ga-PSMA-11 PET/CT was compared based on subjective scoring and objective parameters. Subjective scoring was conducted from background noise and lesion prominence using a 5-point scale. Objective parameters were evaluated by SUVmax, SUVmean, the standard deviation (SD) of SUV, and the signal-to-noise ratio (SNR) of liver and gluteus maximus. The SUVmax of the recurrent lesions was also measured.The liver SD of the total-body [68 Ga]Ga-PSMA-11 PET/CT was significantly lower than that of conventional [68 Ga]Ga-PSMA-11 PET/CT, the SNR was significantly higher than that of conventional [68 Ga]Ga-PSMA-11 PET/CT, and the subjective evaluation was significantly better than that of conventional [68 Ga]Ga-PSMA-11 PET/CT. The detection rate of total-body [68 Ga]Ga-PSMA PET/CT for biochemical recurrence of prostate cancer was significantly higher than that of conventional [68 Ga]Ga-PSMA-11 PET/CT (91.0% vs. 74.0%, P = 0.003). Total-body [68 Ga]Ga-PSMA-11 PET/CT had better detection efficiency for patients with a Gleason score ≤ 8 or PSA ≤ 2 ng/ml. The advantages of diuretic-delayed total-body [68 Ga]Ga-PSMA-11 PET/CT were more obvious.Total-body [68 Ga]Ga-PSMA-11 PET/CT could significantly improve the detection rate compared with conventional [68 Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.